Table 1. Characteristics of included studies.
| First author (year) | N (hAECs/saline) | Animal (age/gender) | Ble Dose (route) | Cell source | Cell Dose (×106) | Time (route) | Cull time |
|---|---|---|---|---|---|---|---|
| Moodley 2010 [5] | 8/8 | SCID mice (8 weeks/?) | 0.15 mg (i.n.) | hAECs (term) | 1 | 24 h/14 d (i.v.) | 2/4 w after Ble |
| Lim 2013 [9] | 8/8 | C57/BL6 mice (8 to 10 weeks/female) | 0.3 U (i.n.) | hAECs (term/preterm) | 4 | 24 h (i.p.) | 7/14 d after Ble |
| Vosdoganes 2013 [10] | 8/8 | C57BL/6 mice (6 to 8 weeks/female) | 0.03 U/kg (i.n.) | hAECs (term) | 4 | 7/14 d (i.p.) | 14 d after Ble |
| Tan 2014 [11] | 6/6 | C57BL/6 mice (6 to 8 weeks/female) | 0.3 U (i.n.) | hAECs | 4 | 24 h (i.p.) | 1/3/5/7 d after Ble |
| Tan 2017 [12] | 19/19 | C57BL/6 mice (8 to 12 weeks/female) | 15 IU (i.n.) | hAECs (term) | 4 | 24 h (i.p.) | 1/3/5/7 d after Ble |
| Murphy 2012 [13] | 23/15 | wild-type mice (6 to 8 weeks/female) | 7 U/kg (i.n.) | hAECs | 4 | 24 h (i.p.) | 7/14 d after Ble |
| Moodley 2013 [14] | 8/8 | C57BL/6 mice (8 weeks/female) | 0.15 mg (i.n.)* | hAECs (P0/P5) | 1 | 72 h (i.v.) | 1/3 w after cell injection |
| Zhu 2016 [8] | ? | C57BL/6 mice (6 to 8 weeks/female) | 0.3 IU (i.n.) | hAECs (term/preterm) | 4 | 24 h (i.p.) | 14 d after Ble |
| Murphy 2011 [15] | 14/14 | C57BL/6 mice (6 weeks/female) | 8 U/kg (i.n.) | hAECs | 4 | 24 h (i.p.) | 7/14 d after Ble |
hAECs: human amniotic epithelial cells
i.v.: intravenous injection
i.p.: intraperitoneal injection
i.n.: intranasal; and
Ble: bleomycin.
*Bleomycin was administered at two time points, with a one-week interval between the first and the second injections.